肿瘤微环境中 TGFβ对免疫细胞的极化作用。
The polarization of immune cells in the tumour environment by TGFbeta.
机构信息
Yale University School of Medicine, 300 Cedar Street, TAC S-569, PO BOX 208011, New Haven, Connecticut 06520, USA.
出版信息
Nat Rev Immunol. 2010 Aug;10(8):554-67. doi: 10.1038/nri2808. Epub 2010 Jul 9.
Abstract
Transforming growth factor-beta (TGFbeta) is an immunosuppressive cytokine produced by tumour cells and immune cells that can polarize many components of the immune system. This Review covers the effects of TGFbeta on natural killer (NK) cells, dendritic cells, macrophages, neutrophils, CD8(+) and CD4(+) effector and regulatory T cells, and NKT cells in animal tumour models and in patients with cancer. Collectively, many recent studies favour the hypothesis that blocking TGFbeta-induced signalling in the tumour microenvironment enhances antitumour immunity and may be beneficial for cancer therapy. An overview of the current drugs and reagents available for inhibiting TGFbeta-induced signalling and their phase in clinical development is also provided.
摘要
转化生长因子-β（TGFβ）是一种免疫抑制细胞因子，由肿瘤细胞和免疫细胞产生，可使免疫系统的许多成分发生极化。本综述涵盖了 TGFβ在动物肿瘤模型和癌症患者中对自然杀伤（NK）细胞、树突状细胞、巨噬细胞、中性粒细胞、CD8(+)和 CD4(+)效应和调节性 T 细胞以及 NKT 细胞的影响。总的来说，许多最近的研究支持这样一种假设，即阻断肿瘤微环境中 TGFβ诱导的信号转导可增强抗肿瘤免疫，可能对癌症治疗有益。本文还概述了目前用于抑制 TGFβ诱导的信号转导的药物和试剂及其在临床开发中的阶段。
相似文献
1
The polarization of immune cells in the tumour environment by TGFbeta.
Nat Rev Immunol. 2010 Aug;10(8):554-67. doi: 10.1038/nri2808. Epub 2010 Jul 9.
2
TGFβ in T cell biology and tumor immunity: Angel or devil?
Cytokine Growth Factor Rev. 2014 Aug;25(4):423-35. doi: 10.1016/j.cytogfr.2014.07.014. Epub 2014 Jul 29.
3
Regulatory T cell: a protection for tumour cells.
J Cell Mol Med. 2012 Mar;16(3):425-36. doi: 10.1111/j.1582-4934.2011.01437.x.
4
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
J Exp Med. 2005 Oct 17;202(8):1075-85. doi: 10.1084/jem.20051511.
5
Transforming growth factor-beta regulation of immune responses.
Annu Rev Immunol. 2006;24:99-146. doi: 10.1146/annurev.immunol.24.021605.090737.
6
Transforming Growth Factor-β Signaling in Immunity and Cancer.
Immunity. 2019 Apr 16;50(4):924-940. doi: 10.1016/j.immuni.2019.03.024.
7
Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
PLoS One. 2011;6(9):e22842. doi: 10.1371/journal.pone.0022842. Epub 2011 Sep 6.
8
Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbeta.
PLoS One. 2010 Aug 19;5(8):e12281. doi: 10.1371/journal.pone.0012281.
9
An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Hum Gene Ther. 2019 Sep;30(9):1117-1132. doi: 10.1089/hum.2019.059. Epub 2019 Jul 1.
10
Tumor-Derived TGFβ Alters the Ability of Plasmacytoid Dendritic Cells to Respond to Innate Immune Signaling.
Cancer Res. 2018 Jun 1;78(11):3014-3026. doi: 10.1158/0008-5472.CAN-17-2719. Epub 2018 Mar 9.
引用本文的文献
1
A fibroblast-centric network drives cold fibrosis in the tumor microenvironment of lung squamous cell carcinoma.
bioRxiv. 2025 Aug 25:2025.08.25.668405. doi: 10.1101/2025.08.25.668405.
2
Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs.
Br J Cancer. 2025 Sep 1. doi: 10.1038/s41416-025-03162-7.
3
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.
BMJ Oncol. 2025 Aug 4;4(1):e000566. doi: 10.1136/bmjonc-2024-000566. eCollection 2025.
4
Biomolecule-functionalized dental implant surfaces: Towards augmenting soft tissue integration.
Bioact Mater. 2025 Jul 26;53:540-590. doi: 10.1016/j.bioactmat.2025.07.005. eCollection 2025 Nov.
5
Assessment of Kynurenine Pathway Enzyme Activity in Ocular Diseases: Associations with Cataract, Diabetes, Glaucoma, and Pseudoexfoliation Syndrome.
J Clin Med. 2025 Jun 26;14(13):4529. doi: 10.3390/jcm14134529.
6
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models.
Gut Liver. 2025 Apr 3;2(1). doi: 10.1038/s44355-025-00018-y.
7
How Do Cancer Cells Create Cancer-Associated Fibroblast Subtypes? Impacts of Extracellular Vesicles on Stromal Diversity.
Cancer Sci. 2025 Sep;116(9):2347-2361. doi: 10.1111/cas.70133. Epub 2025 Jun 25.
8
Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment.
J Transl Med. 2025 Jun 23;23(1):697. doi: 10.1186/s12967-025-06744-4.
9
Identification of Cancer Associated Fibroblasts Related Genes Signature to Facilitate Improved Prediction of Prognosis and Responses to Therapy in Patients with Pancreatic Cancer.
Int J Mol Sci. 2025 May 19;26(10):4876. doi: 10.3390/ijms26104876.
10
Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling.
Nat Commun. 2025 May 27;16(1):4908. doi: 10.1038/s41467-025-60092-x.
本文引用的文献
1
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.
2
T(H)17 cells in tumour immunity and immunotherapy.
Nat Rev Immunol. 2010 Apr;10(4):248-56. doi: 10.1038/nri2742.
3
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
N Engl J Med. 2010 Mar 11;362(10):875-85. doi: 10.1056/NEJMoa0905680.
4
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
J Exp Med. 2010 Mar 15;207(3):651-67. doi: 10.1084/jem.20091921. Epub 2010 Feb 15.
5
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
J Exp Med. 2010 Mar 15;207(3):637-50. doi: 10.1084/jem.20091918. Epub 2010 Feb 15.
6
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Neuro Oncol. 2010 Jan;12(1):7-13. doi: 10.1093/neuonc/nop009. Epub 2009 Nov 5.
7
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
Clin Cancer Res. 2010 Feb 15;16(4):1191-205. doi: 10.1158/1078-0432.CCR-09-1634. Epub 2010 Feb 9.
8
Macrophages, innate immunity and cancer: balance, tolerance, and diversity.
Curr Opin Immunol. 2010 Apr;22(2):231-7. doi: 10.1016/j.coi.2010.01.009. Epub 2010 Feb 9.
9
Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha.
Immunology. 2009 Nov;128(3):439-50. doi: 10.1111/j.1365-2567.2009.03134.x.
10
Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Clin Cancer Res. 2010 Jan 1;16(1):164-73. doi: 10.1158/1078-0432.CCR-09-1758. Epub 2009 Dec 22.
Zotero 插件